NewsBenzingaXylem prévoit un BPA ajusté T4 de 1,39 $ à 1,44 $ contre 1,63 $ estimé ; anticipe un chiffre d’affaires de 2,300 Md$ contre 2,446 Md$ estimé Xylem prévoit un BPA ajusté T4 de 1,39 $ à 1,44 $ contre 1,63 $ estimé ; anticipe un chiffre d’affaires de 2,300 Md$ contre 2,446 Md$ estimé Benzinga 2026.10.27 10:57 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform Quanterix Affirms FY2026 Sales Guidance of $142.000M-$146.000M vs $143.357M Est
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform